ARMISTICE CAPITAL, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001601086

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHigh Turnover how tags are computed

Q3 2026 · 335 positions · Total reported value $7.32B · Top-10 concentration 68.7% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 80.3% · 158 new · 82 cut · 148 exited

Active Share (vs S&P 500): 94.8% · vs QQQ: 95.6% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -2.0% · vs SPY -4.1% · Prev Value $7.59B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +0.3% · vs SPY -1.9% · Latest Value $7.32B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, ARMISTICE CAPITAL, LLC disclosed 335 equity positions with a combined reported value of $7.32B. The filing implies a focused portfolio: its ten largest positions account for 68.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / High Turnover.

The largest disclosed positions as of Q3 2026 were SPY ($2.55B), IWM ($1.83B), SUPN ($109.67M). By sector, the heaviest allocations are Health Care 26.1%, Technology 6.7%. Versus the prior quarter, allocation shifted toward Other (+5.5pp) and away from Technology (-0.6pp), Industrials (-1.3pp).

Versus the prior quarter, ARMISTICE CAPITAL, LLC opened 158 new positions, trimmed 82 and fully exited 148, a turnover rate of 80.3% of positions. The portfolio's overlap with the prior quarter was 37% of names.

The largest new positions opened in Q3 2026 were TLX ($18.32M), GEHC ($16.30M), BNTX ($16.12M).

Of the 148 positions fully exited versus the prior quarter, the largest were HUM ($28.81M), ILMN ($16.02M), PBH ($15.88M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • TLX TELIX PHARMACEUTICAL LTD · $18.32M
  • GEHC GE HEALTHCARE TECHNOLOGIES I · $16.30M
  • BNTX BIONTECH SE · $16.12M
  • SPSC SPS COMM INC · $15.73M
  • DKS DICKS SPORTING GOODS INC · $13.07M
  • LION LIONSGATE STUDIOS CORP · $8.27M
  • MBC MASTERBRAND INC · $7.25M
  • XMTR XOMETRY INC · $5.52M

Fully Exited (vs previous quarter)

  • HUM HUMANA INC · prev qtr: $28.81M
  • ILMN ILLUMINA INC · prev qtr: $16.02M
  • PBH PRESTIGE CONSMR HEALTHCARE I · prev qtr: $15.88M
  • FWONK LIBERTY MEDIA CORP DEL · prev qtr: $15.71M
  • ITGR INTEGER HLDGS CORP · prev qtr: $15.68M
  • LYV LIVE NATION ENTERTAINMENT IN · prev qtr: $14.98M
  • NVO NOVO-NORDISK A S · prev qtr: $14.96M
  • TWST TWIST BIOSCIENCE CORP · prev qtr: $14.61M

Insider Transactions (Form 4)

Latest ARMISTICE CAPITAL, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Armistice Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 325 US equity positions with a combined value of $7.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-100464 (status: Approved), registered 2015-07-02
  • Regulatory AUM (Form ADV): $4.72B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: armisticecapital.com

Portfolio Structure

  • 325 positions · $7.59B reported value (Q2 2026)
  • Top 10 holdings = 65.2% of reported value
  • Largest position: SPY (STATE STR SPDR S&P 500 ETF T) at 31.5%
  • Average position size: $23.35M

Sector Tilt

  • Health Care 29.3%
  • Information Technology 7.4%
  • Consumer Discretionary 5.2%
  • (classified holdings cover 45% of value)

Quarterly Activity

  • Q2 2026: 168 new, 72 added, 65 reduced, 96 exited
  • 20 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: Aggressive bullish tilt, with significant additions to large-cap U.S. equity ETFs (SPY, IWM), suggesting strong confidence in broad market upside. 2. Key moves: - Added: SPY (+4.7% shares), IWM (+13.8% shares), AGIO (+7.4% shares), PTCT (+96.6% shares), IRWD (+7.7% shares). - Reduced: SUPN (-3.7% shares), CYTK (-1.8% shares), RIGL (-8.1% shares), INCY (-33.3% shares), NBIX (-6.7% shares). 3. Portfolio structure: Passive-heavy (SPY/IWM dominate), biotech/Health Care overweight (6/10 top holdings), high risk appetite (concentrated positions, volatile biotech bets). 4. Per-holding one-liner: - SPY: S&P 500 ETF (U.S. large-cap equities). - IWM: Russell 2000 ETF (U.S. small-cap equities). - SUPN: Neurology-focused pharma (unverified). - AGIO: Cancer metabolism drugs (unverified). - PTCT: Rare disease therapeutics (unverified). - CYTK: Cardiovascular muscle drugs (unverified). - RIGL: Autoimmune disease treatments (unverified). - INCY: Oncology/immunology drugs (unverified). - NBIX: Neuroendocrine therapies (unverified). - IRWD: GI motility drugs (unverified). 5. Style summary: Aggressive, market-cap-weighted U.S. equity exposure with concentrated biotech bets, favoring large-caps and selectively adding high-conviction healthcare names.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 03:59

Sector Allocation

Health Care 26.1%
Technology 6.7%
Energy 0.1%
Financials 0.1%
Other 60.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.35M $2.55B 34.91%
34.91%
Add
2 6.60M $1.83B 25.07%
25.07%
Add
3 2.55M $109.67M 1.50%
1.50%
Reduce
4 2.58M $85.72M 1.17%
1.17%
Add
5 1.30M $84.05M 1.15%
1.15%
Add
6 1.18M $77.79M 1.06%
1.06%
Reduce
7 1.54M $73.96M 1.01%
1.01%
Reduce
8 600.04K $72.82M 0.99%
0.99%
Reduce
9 500.00K $70.92M 0.97%
0.97%
Reduce
10 15.00M $59.55M 0.81%
0.81%
Add
11 1.44M $56.38M 0.77%
0.77%
Reduce
12 1.62M $54.89M 0.75%
0.75%
Add
13 888.69K $51.15M 0.70%
0.70%
Reduce
14 92.02K $46.38M 0.63%
0.63%
Reduce
15 185.83K $46.30M 0.63%
0.63%
Reduce
16 5.72M $46.08M 0.63%
0.63%
Reduce
17 2.68M $43.14M 0.59%
0.59%
Reduce
18 56.74K $43.02M 0.59%
0.59%
Reduce
19 720.00K $42.39M 0.58%
0.58%
Add
20 700.00K $42.38M 0.58%
0.58%
Reduce
21 1.60M $40.21M 0.55%
0.55%
Add
22 108.34K $37.77M 0.52%
0.52%
Reduce
23 724.00K $34.88M 0.48%
0.48%
Add
24 1.14M $34.41M 0.47%
0.47%
Reduce
25 83.89K $34.11M 0.47%
0.47%
Add
26 3.62M $34.10M 0.47%
0.47%
Add
27 824.00K $33.97M 0.46%
0.46%
Reduce
28 486.65K $33.34M 0.46%
0.46%
Reduce
29 64.66K $33.16M 0.45%
0.45%
Reduce
30 90.00K $33.04M 0.45%
0.45%
Reduce
31 500.00K $32.73M 0.45%
0.45%
Add
32 95.00K $32.69M 0.45%
0.45%
Reduce
33 4.50M $32.51M 0.44%
0.44%
Add
34 660.70K $31.22M 0.43%
0.43%
Add
35 876.00K $29.79M 0.41%
0.41%
Reduce
36 692.00K $29.01M 0.40%
0.40%
Reduce
37 3.24M $28.67M 0.39%
0.39%
Reduce
38 2.36M $28.51M 0.39%
0.39%
Add
39 357.04K $28.36M 0.39%
0.39%
Add
40 6.36M $28.26M 0.39%
0.39%
Hold
41 1.95M $27.90M 0.38%
0.38%
Reduce
42 250.00K $26.89M 0.37%
0.37%
Add
43 13.75M $26.68M 0.36%
0.36%
Reduce
44 177.70K $25.83M 0.35%
0.35%
Reduce
45 120.18K $24.64M 0.34%
0.34%
Reduce
46 1.54M $23.62M 0.32%
0.32%
Reduce
47 6.00M $23.16M 0.32%
0.32%
Add
48 160.00K $22.79M 0.31%
0.31%
Add
49 2.10M $22.45M 0.31%
0.31%
Reduce
50 31.99K $21.59M 0.29%
0.29%
Reduce

FAQ

What did ARMISTICE CAPITAL, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, ARMISTICE CAPITAL, LLC reported 335 equity positions worth $7.32B in aggregate; its largest disclosed positions were SPY ($2.55B), IWM ($1.83B), SUPN ($109.67M).

How large is ARMISTICE CAPITAL, LLC's portfolio?

ARMISTICE CAPITAL, LLC reported $7.32B of long equity holdings across 335 positions as of 2026-Q3. Top-10 holdings account for 68.7% of reported value.

What is ARMISTICE CAPITAL, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/armistice-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →